The German Lipid Apheresis Registry - remaining to be established

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 59-61

  Schettler, Volker ^a   Jaeger, Beate R ^b   Klingel, Reinhard ^c  

^a Center of Nephrology Göttingen   (Germany)

^b Medizinisches Versorgungszentrum   (Germany)

^c Apheresis Research Institute   (Germany)

Author keywords

Indication for lipid apheresis; Lipid apheresis; Lipid apheresis registry

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APHERESIS; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPUTER PROGRAM; DIET THERAPY; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; FINANCIAL MANAGEMENT; GERMANY; HEALTH CARE DISTRIBUTION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; TREATMENT INDICATION;

BLOOD COMPONENT REMOVAL; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; HYPERLIPIDEMIAS; LIPIDS; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; REGISTRIES; TREATMENT OUTCOME;

EID: 73049094786     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71813-6     Document Type: Article

References (16)

1. Keller C. LDL-apheresis: results of longterm treatment and vascular outcome. Atherosclerosis 86 1 (1991) 1-8
2. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 198 2 (2008) 247-255
3. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6 3 (2009) 229-239
4. Bestehorn K. [Medical registries]. Med Klin (Munich) 100 11 (2005) 722-728
5. Schettler V., Wieland E., Armstrong V.W., Kleinoeder T., Grunewald R.W., and Muller G.A. First steps toward the establishment of a German low- density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 6 5 (2002) 381-383
6. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 194 1 (2007) 1-45
7. Fletcher B., Berra K., Ades P., Braun L.T., Burke L.E., Durstine J.L., et al. Managing abnormal blood lipids: a collaborative approach. Circulation 112 20 (2005) 3184-3209
8. Snyder J.J., and Collins A.J. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol 20 7 (2009) 1614-1622
9. Stegmayr B., Ptak J., Wikstrom B., Berlin G., Axelsson C.G., Griskevicius A., et al. World apheresis registry 2003-2007 data. Transfus Apher Sci 39 3 (2008) 247-254
10. Norda R., Axelsson C.G., Axdorph U., Berlin G., Wikstrom B., and Stegmayr B. Recognition of intercenter differences may help develop best practice. Ther Apher Dial 12 5 (2008) 347-354
11. Korach J.M., Guillevin L., Petitpas D., Berger P., and Chillet P. Apheresis registry in France: indications, techniques, and complications. French Registry Study Group. Ther Apher 4 3 (2000) 207-210
12. Rock G., Clark B., and Sutton D. The Canadian apheresis registry. Transfus Apher Sci 29 2 (2003) 167-177
13. Watson M.S., Epstein C., Howell R.R., Jones M.C., Korf B.R., McCabe E.R., et al. Developing a national collaborative study system for rare genetic diseases. Genet Med 10 5 (2008) 325-329
14. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FHLDL-Apheresis Study Group. Am J Cardiol 82 12 (1998) 1489-1495
15. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis (2009)
16. Drager J., Petzold S., Ristau, and Trepte S. [QUASA-the apheresis registry]. Z Kardiol 92 Suppl 3 (2003) III68-III72